-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte's Zynyz Gets UK Health Regulator's Nod for Advanced Anal Cancer

MT Newswires·11/11/2026 22:48:09
Listen to the news
10:48 PM EST, 11/11/2026 (MT Newswires) -- Incyte Biosciences secured approval from the UK's Medicines and Healthcare products Regulatory Agency, or MHRA, for Zynyz to treat patients with squamous cell carcinoma of the anal canal. The MHRA issued the latest approval on Nov. 5, according to a Wednesday release. Zynyz, or retifanlimab, is already authorized in the UK for treating advanced Merkel cell carcinoma, a rare form of skin cancer. The UK regulator said a study involving 308 people demonstrated that retifanlimab combined with chemotherapy was more effective and increased the lifespan of patients with the advanced anal cancer without their condition getting worse, compared with placebo plus chemotherapy.